Introduction
============

Phopsphotidylinositol 3-kinase (PI3ks) is a grouping of lipid kinases to control signalling pathways occupied in cell proliferation, adhesion, survival, and motility. Phosphatidylinositol 3-kinase (PI3K), is a main downstream signalling component of tyrosine kinases (RTKs) as a growth factor receptor. Tainted mutation and expression of PI3-kinase/AKT pathway components have been occupied in diverse fellow malignancies [@B1],[@B2]. Previously published article determined PTEN and epidermal growth factor receptor (HER3) as surrogate markers in patients, which have HER2-overexpressing MBC, and it has been suggested that these markers may affect in the PI3K pathway [@B3]. The previous published articles establish that the *PIK3CA* is furthermost oncogene mutated in breast carcinoma and provision an impress for *PIK3CA* in carcinogenesis [@B4].

So far, mutations of *PIK3CA* stated in breast cancers, which are gathered in two main hotspot areas in exons 9 and 20, consistent to tyrosine kinase and helical domains [@B4],[@B5]. In more than 80% of the cases, mutations are gathered in the helical domain and kinase domain which encoded exon 9 and exon 20, respectively. To continue, several hotspot mutations of mentioned exons specifically H1047R, E545K and E542K were demonstrated to operate the PI3K/AKT pathway over the AKT phosphorylation [@B6]-[@B9]. However, this study has focused mainly on the amplification of *PIK3CA* in breast carcinomas. We defined the occurrence ratio of *PIK3CA* gene copy numbers in breast carcinoma in order to make a comparison with recent published data. Lately, it has been publicized that PI3K is linked to the cellular proliferation and transformation in some cancer cell lines, which contain breast carcinoma, myelogeneous leukemia and AIDS-related Kaposi Sarcoma, prostate carcinoma and hepatocellular carcinoma [@B10]-[@B14]. More recently, superior PI3K protein expression and activity have been identified in glioblastomas, colorectal and lung cancer [@B15],[@B16]. In consequence, these findings recommended the significance of the PI3K in the development of malignant neoplasia. For that reason, we studied the expression layout of PI3K protein expression in 50 breast carcinoma.

Material and method
===================

Tumor samples and cell lines
----------------------------

Formalin-fixed, paraffin-implanted tissue samples from 50 patients have been used for this study. The tumors selected for this study were 50 breast carcinoma. All tumours histological classification was established in the World Health Organization (WHO) system.

DNA isolation
-------------

Firstly, Paraffin-embedded tissue sections were treated at room temperature for 5 minutes with xylene, pursued by digestion with Proteinase K at 56ºC for 18 hours. Genomic DNA was consequently extracted employing QIAamp® DNA Mini Kit (Qiagen, Germany). The events were achieved matching to the directions of the manufacturer\'s.

Polymerase Chain Reaction (PCR)
-------------------------------

Genomic DNA was amplified by real-time PCR using the specific *PIK3CA* gene amplifying primers. We have used *β-actin*as a reference gene for control. Primers and Taqman probes were as follows, *PIK3CA*, 5′-AAATGAAAGCTCACTCTGGAATTCC-3\' (forward), and 5′-TGTGCAATTCCTATGCAATCG-3′ (reverse), and 5′-6-carboxyfluorescein-CACTGCACTGTTAATAACTCTCAGCAGGCAAA tetramethylrhodamine-3′ (Taqman probe) [@B17]. Also for β-actin, 5\'-TCACCCACACTGTGCCCCATCTACGA-3′ (forward), 5′-TCGGTGAGGATCTTCATGAGGTA-3′ (reverse), and 5′-6-carboxyfluorescein-ATGCCCTCCCCCATGCCATCC-tetramethylrhodamine-3′ (Taqman probe) [@B17]. Entire primers as well as Taqman probes were procured from Operon Biotechnologies (Aitbiotech, Singapore). Final volume of 25µl was used for PCR reaction as referred in Table [1](#T1){ref-type="table"}. The PCR cycling was designed by the following steps, denaturation at 95º C for 2 minutes, 50 cycles of 95º of centigrade for thirty seconds and 60º of centigrade for forty five seconds. The comparative *PIK3CA*copy number of the sample was calculated by considering 2.0 as the normal diploid DNA copy number. The cutoff value of *PIK3CA* copy number gain was set at more or equal to 4.0 copies [@B18],[@B19].

To continue, for immunohictochemical analysis the slides were treated with 3-aminopropyltrimethoxysilane (APES). Paraffin-embedded tissue sections of thickness 4.0µm were cut using a Leica rotary microtome RM2135 (Leica Microsystems, Germany) and mounted on slides. The slides were stored at 4 ºC after drying. Briefly, the slides with paraffin sections were placed in 60ºC oven for 30 minutes. Then the tissue sections were deparaffinized and hydrated by crossing over xylene and a stratified series of ethanol. Antigen recovery as presented for 25 minutes at 100ºC in Tris-EDTA (pH9) buffer solution, into a microwave oven. After heat-induced epitope retrieval, the slides with tissue sections were allowed for 30 minutes to cool at room temperature. Then, tissue sections were washed in Tris-buffered saline with 0.1% Tween-20 (TBS-T), pH7.6. Then, incubated sections with 3% H~2~O~2~ solution for 10 minutes and after those sections were incubated in 3% BSA. After that primary antibody against PI3K (p110α 1:50) was enhanced and then incubated for 2 hours. Then, primary antibody enhancer (QIAgene) was enhanced and incubated about 20 minutes at room temperature. Then, tissues were embrocated with TBS-T and incubated in 3, 3′-diaminobenzidine (DAB) substrate chromogen system (UltraVision Plus Detection System; Thermo Fisher Scientific, Fermont, CA) for 5-20 minutes until the brown color end-products were observed and sections were washed in 2x dH~2~O. The tissue sections were finally counterstained with hematoxylin for 5 seconds and washed in running tap water for 2 minutes. Finally the tissues were dehydrated. Rabbit monoclonal anti-PI3K p110α antibody (clone C13F8, Cell signalling technology, USA) was used at a dilution of 1:50. Antigen detection was performed at 100ºC for 25 minutes at pH 6.0, 10mM sodium citrate buffer, in a microwave oven. Finally, tissue sections were incubated with anti-PI3K p110α antibody for one hour at room temperature.

The relationship between *PIK3CA* gene copy numbers and PI3K p110α protein expression and clinico-pathological records were evaluated by Fisher\'s exact test. Kruskal-Wallis and Mann-Whitney are the two statistical tests which were used for the correlation analysis and p˂ 0.05 was presumed as statistically significant. SPSS 20.0 parameters (SPSS Inc., USA) were used for statistical analysis.

Result
======

*PIK3CA* gene copy numbers and PI3K p110α protein expression in breast carcinoma
--------------------------------------------------------------------------------

*PIK3CA* gene amplification has been studied in different type of human carcinomas, for example; uterine cancer [@B20], cell lung cancer [@B21], nasopharyngeal carcinoma [@B22] and endometrial cancer [@B23]. One of our aims was to determine the gene copy number rate of *PIK3CA* in breast carcinoma. Hence, genomic DNA from 50 breast carcinoma and 10 normal blood samples was used to determine the frequency of an increased copy number of *PIK3CA* gene. Our results suggest that, 36 out of 50 (72%) samples shows an increase in *PIK3CA* gene amplification in breast carcinoma and *PIK3CA* gene copy numbers were lower than 4, in 14 out of 50 (28%) samples. Results obtained from normal human blood samples showed that there were no significant positive gene copy numbers identified in normal blood DNA samples and *PIK3CA* gene copy numbers were lower than 4 in all samples.

We estimated expression of PI3K p110α in breast carcinoma in 50 breast carcinoma tissues. The immunohistochemical scores of 0 and 1+ staining were considered as negative and 2+ and 3+ staining were considered positive. As results shows, 12 out of 50 (24%) of breast carcinoma samples have positive staining and 38 samples (76%) were negative. Figure [1](#F1){ref-type="fig"}, shows negative control, weak (1+) and moderate (2+) staining of PI3K p110α protein in breast carcinoma tissue.

Relationship between *PIK3CA* gene copy number, PI3K p110α protein expression, age, race and histological types
---------------------------------------------------------------------------------------------------------------

In the present study, the relationship between *PIK3CA* gene amplification, age, race and histological type was analysed in breast carcinoma. Statistical analysis showed that there is no significant relationship between *PIK3CA* gene amplification, race (p=0.630) and histological type (p=0.731) in breast carcinoma, but there is a significant relationship between *PIK3CA* gene amplification and age (p=0.003) in breast carcinoma (Table [2](#T2){ref-type="table"}).

Also, we have done correlation between PI3K p110α protein expression, age, race and histological type in breast carcinoma, which statistical analysis showed that there is no significant relationship between PI3K p110α expression, age (p=0.284), race (p=0.546) and histological type (p=0.285) in breast carcinoma (Table [3](#T3){ref-type="table"}).

Discussion
==========

To find out gene copy numbers of the *PIK3CA*, we carried out real-time PCR over 50 breast tumor samples. Gene amplification is well accepted as a later occurrence in tumor progression [@B24],[@B25].

Overall, we found a high frequency of *PIK3CA* gene copy numbers in breast carcinoma samples. Among the 50 cases, 36 (72%) showed a large amount of gene copy numbers in comparison to normal controls. Previously published data, specified PI3K pathway distorted in a large amount among breast carcinoma patients [@B26]-[@B28]. Though, the occurrence of gene copy number was much more than results identified in earlier studies (1-9-14%) [@B29],[@B30]. *PIK3CA* amplification and mutation were nearly equally individual events and as they signify independent methods for enriching PI3K activity, an upper incidence of copy number may possibly clarify the inferior occurrence of *PIK3CA* amplification in this group compared to those in further reports. Among other types of cancers, genetic analysis of *PIK3CA* amplification were conducted in Japan, *PIK3CA* was over expressed in 73% of primary ovarian clear cell carcinomas [@B31]. In comparison with the previous published data, our data suggest that *PIK3CA* is significant in breast tumorigenesis, serve as a mutual mechanism contributes to the oncogenic activation of *PIK3CA* in breast cancer.

In breast carcinomas, PI3K over expression occurred in 24% of all tumor samples, thereby considered as not over expressed. More recently, studies informed that PI3K is not over expressed in melanocytic lesions [@B32]. Our data are consistent with the previous studies, whereas, p110β and p110α are all over expressed in untransformed cells and tissues, whereas p110δ expression is highly enriched in leukocytes. High levels of p110δ expression have been documented in some solid tumor cell lines, but the functional role is unknown [@B33]. PI3K pathway activation in breast carcinoma was distinguished using p-S6, p-AKT, and PTEN by evaluating of their expression through IHC. The expression of p-S6 and p-AKT was positive in 75% and 69% of breast carcinoma. There was No significant association between PI3K pathway status and breast carcinoma subtype for p-AKT [@B34].

Our data showed no significant association between PI 3-kinase expression and ages, races and histological types in breast carcinoma. Also, no relation between the *PIK3CA* gene copy number, race and histological type has been found, but there is a significant relation between *PIK3CA* gene copy number and age in breast carcinoma has reported, which may due post-transcriptional, translational and protein degradation regulation which shows some genes are produced but not expressed on the cell surface [@B35].

The PI3K pathway deviations are existing in a significant quantity of breast carcinoma patients. Accumulating evidence support that PI3K activation has been affiliated with persistence to ErbB2-targeted therapy, moreover standard cytotoxic therapy in breast carcinoma, and the addition of novel PI3K pathway inhibitors (e.g., PX-866, BEZ235, and XL147) which are expected to have superior therapeutic ability to treat patients resistant to standard therapies [@B36],[@B37]. Although several PI3K activation biomarkers have been proposed such as p-Akt and PIP3, these biomarkers are either not specific or difficult to measure in clinical practice [@B38]. There was no significant correlation observed amongst *PIK3CA* mutation and age, differentiation, histological type and lymph node metastasis in a research has done in China [@B39]. Our research outcomes are not similar to the prior study, Saal et al. (2005); found positive significance between *PIK3CA* mutations and expression in breast cancer. We believe, variations in samples will be the reason of differences between our and the other studies, as their experiment was carried out on *PIK3CA* exons such as 1, 2, 4, 5, 7, 9, 12, 13, 18, 20, which were included intron-exon boundaries and their method were based on PCR as well as gene sequencing of exons so it can be the cause of inconsistency with our research. Our study also did not have any focus on mutations and we used primers for amplification of *PIK3CA* on exon 21. In contrast, another study done in exons 9 and 20 reported no significant relationship between *PIK3CA* mutations and some clinicopathologic characteristics, such as age, lymph node metastases, tumor size, ER and PR status, p53 expression and mutation in breast cancer [@B40].

Treatment and Survival
----------------------

Based on survival statistics during of 5-year, which has been issued between 1975 to 2008 in the *SEER Cancer Statistics Review*; breast cancer therapy includes breast-conserving surgery (BCS) or mastectomy. Mastectomy is similar as long-term survival, when BCS is appropriately used for provincial or restricted cancers [@B41].

Limited of diagnosis are on age in women (20-45%), who decided to have breast reconstruction assume mastectomy elect, with each tissue flap or an implant or a mixture of the both [@B42]-[@B46].

Amongst women make a diagnosis in early stage (I or II) of breast carcinoma, 57% accept breast-conversing surgery, 36% assume a mastectomy , around 6% endure no surgical usage, and approximately 1% take no conduct. In contrast, across patients having late stage of breast cancer (III or IV), 13% accept breast-conserving surgery, 60% undertake mastectomy treatment, 18% assume no surgical demeanor, and 7% receive no treatment at all.

The totall comparative survival percentage in 5-year for patients (female) with breast cancer has enhanced from 75.1% to 90.0% between 1975 and 1977 to 2001 over 2007. The growth is mostly due to developments in therapy (ie, hormone therapy and chemotherapy), also to previously identified results from the extensive usage of mammography [@B47]. Moreover, to stage, epidermal growth factor receptor 2 (HER2) status in human, aspects which affect survival comprise hormone receptor status, and tumor grade.
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###### 

Protocol and amount of material used in real-time PCR

                           X1       X2
  ------------------------ -------- --------
  Taq buffer with KCL      2.5μl    5μl
  MgCl~2~                  3μl      6μl
  dNTPs                    0.5μl    1μl
  Forward primer           0.75μl   1.5μl
  Reverse primer           0.75μl   1.5μl
  Taqman probe             0.6μl    1.2μl
  Taq DNA polymerase       1.25μl   2.5μl
  DNA                      2μl      2μl
  Double-distilled water   13.6μl   27.2μl
  Total volume             25μl     50μl

###### 

Correlation between *PIK3CA* gene copy numbers, age, race and histological types in breast carcinoma

  PI3K Copy No              Number   Mean Rank   P
  ------------------------- -------- ----------- -------
  Age^\*^                                        
  =\<48                     28       20.21       0.003
  \>48                      22       32.23       
  Race^\*^                                       
  Group1                    8        20.00       
  Group2                    28       25.79       0.630
  Group3                    10       27.30       
  Group4                    4        30.00       
  Histological Type^\*\*^                        
  I                         20       27.30       
  II                        20       23.70       0.731
  III                       10       25.50       

^\*^Mann-Whitney test / ^\*\*^Kruskal-Walley test

###### 

Correlation between PI3K p110α expression, age, race and histological grade in breast carcinoma

  PI3K p110α                Number   Mean Rank   P
  ------------------------- -------- ----------- -------
  Age^\*^                                        
  =\<48                     28       23.79       0.284
  \>48                      22       27.68       
  Race^\*^                                       
  Group1                    8        23.50       
  Group2                    28       25.43       0.546
  Group3                    10       23.90       
  Group4                    4        34.00       
  Histological type^\*\*^                        
  I                         20       25.80       
  II                        20       27.90       0.285
  III                       10       20.10       

^\*^Mann-Whitney test / ^\*\*^Kruskal-Walley test
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